Methods and compositions involving miRNA and miRNA inhibitor molecules
AssigneeAsuragen, Inc.
InventorsDavid Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
Claims7
A method for decreasing cell viability or decreasing cell proliferation of a cancer cell in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of a pharmaceutical composition comprising:
- a. a synthetic miR-101 molecule comprising:
- i. an active strand comprising a sequence that is at least 90% identical to mature human miR-101;
- and
- ii. a separate complementary strand that is at least 60% complementary to the active strand and has a 5′-terminal nucleotide that is chemically modified to comprise a lower alkylamine group, and
- b. a pharmaceutically-acceptable excipient.
Dependencies are inferred from the claim text.